“A Good Personal Scientific Relationship”: Philip Morris Scientists and the Chulabhorn Research Institute, Bangkok

Jeff Collin and Ross MacKenzie analyze tobacco industry documents and find that Philip Morris consultants were able to gain access to a Thai research institute that is a WHO Collaborating Centre

ANSI/NISO Z39.99-2017 ResourceSync Framework Specification

This ResourceSync specification describes a synchronization framework for the web consisting of various capabilities that allow third-party systems to remain synchronized with a server’s evolving resources. The capabilities may be combined in a modular manner to meet local or community requirements. This specification also describes how a server should advertise the synchronization capabilities it supports and how third-party systems may discover this information. The specification repurposes the document formats defined by the Sitemap protocol and introduces extensions for them

Development and Expansion of the Natural Resource Data and Information Systems in Support of the Illinois Comprehensive Wildlife Conservation Plan

Project Completion Report 2006, Project: T-02-P-001-Final, 1 February 2003 to 30 September 2006Report issued on: November 2006Submitted to Illinois Department of Natural Resource

Rituximab in refractory chronic inflammatory demyelinating polyneuropathy

© 2020 Wiley Periodicals, Inc. Introduction: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a disorder in which early effective treatment is important to minimize disability from axonal degeneration. It has been suggested that some patients with CIDP may benefit from rituximab therapy, but there is no definitive evidence for this. Methods: Baseline and post–rituximab-therapy neuromuscular Medical Research Council (MRC) sum scores, Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, and functional status were assessed in 11 patients with refactory CIDP. Results: The MRC sum score, INCAT disability score, and functional status improved in all patients after rituximab therapy. Discussion: Our study provides evidence of the efficacy of rituximab therapy in at least some patients with CIDP. A placebo-controlled study to assess the effectiveness of rituximab therapy in CIDP with and without nodal antibodies is required to identify disease markers that predict responsiveness